BBIO Since 2019 Annualized Return and Average Annual Return

BBIO Average Annual Return Chart Since 2019
Growth of $10,000.00
Without Dividends Reinvested Into BBIO

Also see:
• BBIO stock yearly return 2020
• BBIO stock yearly return 2021
• BBIO stock yearly return 2022
• BBIO stock yearly return 2023
• BBIO stock yearly return 2024
• BBIO stock yearly return 2025
• BBIO YTD return
Average Annual Return Benchmarks
Compare BBIO average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
BBIO Share Performance
BBIO Average Annual Return Table Since 2019
Start date: 06/28/2019
End date: 05/11/2026
Start price/share: $26.97
End price/share: $64.68
Dividends collected/share: $0.00
Total return: 139.82%
BBIO Average Annual Return: 13.57%
Starting investment: $10,000.00
Ending investment: $23,981.74
Years: 6.87


BBIO average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
About BridgeBio Pharma Inc
BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company focused on developing transformative medicines for genetic diseases and cancers with clear genetic drivers. Its pipeline includes Acoramidis (AG10) for amyloidosis TTR (ATTR), low-dose infigratinib for achondroplasia, Encaleret for Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418 for LGMD2I (LGMDR9). The company's programs range from early science to advanced clinical trials, aiming to discover, create, test, and deliver these treatments to patients. The BBIO average annual return since 2019 is shown above.

The Average Annual Return on the BBIO average annual return since 2019 page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether BBIO average annual return since 2019 or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the BBIO average annual return calculation with any dividends reinvested as applicable (on ex-dates).
BBIO Current Stock Quote
Quotes delayed 20 minutes

Email EnvelopeFree BBIO Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
Featured Slideshows
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!
Video: Don't Forget Dividends in Average Annual Return!
Average Annual Return Peers
BridgeBio Pharma (BBIO) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

BBLG Average Annual Return
BCAB Average Annual Return
BCDA Average Annual Return
BCLI Average Annual Return
BCRX Average Annual Return
BDSX Average Annual Return
BDTX Average Annual Return
BDX Average Annual Return
BEAM Average Annual Return
BEAT Average Annual Return
More Healthcare companies »
 

BBIO Average Annual Return Since 2019 | www.AverageAnnualReturn.com | Copyright © 2021 - 2026, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.